
# Benchmarking Dimensionality Reduction Techniques for Spatial Transcriptomics

**Korean Title:** ê³µê°„ ì „ì‚¬ì²´í•™ì„ ìœ„í•œ ì°¨ì› ì¶•ì†Œ ê¸°ìˆ ì˜ ë²¤ì¹˜ë§ˆí‚¹

## ğŸ“‹ ë©”íƒ€ë°ì´í„°

**Links**: [[daily/2025-09-18|2025-09-18]] [[keywords/evolved/Pareto optimal analysis|Pareto optimal analysis]] [[keywords/broad/Dimensionality Reduction|Dimensionality Reduction]] [[keywords/broad/Spatial Transcriptomics|Spatial Transcriptomics]] [[keywords/specific/Cholangiocarcinoma|Cholangiocarcinoma]] [[keywords/unique/Cluster Marker Coherence (CMC|Cluster Marker Coherence (CMC]] [[categories/cs.LG|cs.LG]]

## ğŸ·ï¸ ì¹´í…Œê³ ë¦¬í™”ëœ í‚¤ì›Œë“œ
**ğŸš€ Evolved Concepts**: Pareto optimal analysis
**ğŸ”¬ Broad Technical**: Dimensionality Reduction, Spatial Transcriptomics
**ğŸ”— Specific Connectable**: Cholangiocarcinoma
**â­ Unique Technical**: Cluster Marker Coherence (CMC

**ArXiv ID**: [2509.13344](https://arxiv.org/abs/2509.13344)
**Published**: 2025-09-18
**Category**: cs.LG
**PDF**: [Download](https://arxiv.org/pdf/2509.13344.pdf)


## ğŸ·ï¸ ì¶”ì¶œëœ í‚¤ì›Œë“œ



`Dimensionality Reduction` â€¢ 

`Spatial Transcriptomics` â€¢ 

`Cholangiocarcinoma` â€¢ 

`Cluster Marker Coherence (CMC` â€¢ 

`Pareto optimal analysis`



## ğŸ“‹ ì €ì ì •ë³´

**Authors:** 

## ğŸ“„ Abstract (ì›ë¬¸)

arXiv:2509.13344v1 Announce Type: cross 
Abstract: We introduce a unified framework for evaluating dimensionality reduction techniques in spatial transcriptomics beyond standard PCA approaches. We benchmark six methods PCA, NMF, autoencoder, VAE, and two hybrid embeddings on a cholangiocarcinoma Xenium dataset, systematically varying latent dimensions ($k$=5-40) and clustering resolutions ($\rho$=0.1-1.2). Each configuration is evaluated using complementary metrics including reconstruction error, explained variance, cluster cohesion, and two novel biologically-motivated measures: Cluster Marker Coherence (CMC) and Marker Exclusion Rate (MER). Our results demonstrate distinct performance profiles: PCA provides a fast baseline, NMF maximizes marker enrichment, VAE balances reconstruction and interpretability, while autoencoders occupy a middle ground. We provide systematic hyperparameter selection using Pareto optimal analysis and demonstrate how MER-guided reassignment improves biological fidelity across all methods, with CMC scores improving by up to 12\% on average. This framework enables principled selection of dimensionality reduction methods tailored to specific spatial transcriptomics analyses.

## ğŸ” Abstract (í•œê¸€ ë²ˆì—­)

arXiv:2509.13344v1 ë°œí‘œ ìœ í˜•: êµì°¨
ìš”ì•½: ìš°ë¦¬ëŠ” í‘œì¤€ PCA ì ‘ê·¼ë²•ì„ ë„˜ì–´ ê³µê°„ ì „ì‚¬ì²´í•™ì—ì„œ ì°¨ì› ì¶•ì†Œ ê¸°ìˆ ì„ í‰ê°€í•˜ê¸° ìœ„í•œ í†µí•©ëœ í”„ë ˆì„ì›Œí¬ë¥¼ ì†Œê°œí•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë‹´ë‚­ì•” Xenium ë°ì´í„°ì…‹ì—ì„œ PCA, NMF, ì˜¤í† ì¸ì½”ë”, VAE, ê·¸ë¦¬ê³  ë‘ í•˜ì´ë¸Œë¦¬ë“œ ì„ë² ë”© ë°©ë²•ì„ ë²¤ì¹˜ë§ˆí‚¹í•˜ì˜€ìœ¼ë©°, ì ì¬ ì°¨ì› ($k$=5-40)ê³¼ í´ëŸ¬ìŠ¤í„°ë§ í•´ìƒë„ ($\rho$=0.1-1.2)ë¥¼ ì²´ê³„ì ìœ¼ë¡œ ë³€í™”ì‹œì¼°ìŠµë‹ˆë‹¤. ê° êµ¬ì„±ì€ ì¬êµ¬ì„± ì˜¤ì°¨, ì„¤ëª…ëœ ë¶„ì‚°, í´ëŸ¬ìŠ¤í„° ì‘ì§‘ë ¥, ê·¸ë¦¬ê³  ë‘ ê°€ì§€ ìƒˆë¡œìš´ ìƒë¬¼í•™ì  ë™ê¸°ë¶€ì—¬ ì§€í‘œì¸ í´ëŸ¬ìŠ¤í„° ë§ˆì»¤ ì¼ê´€ì„± (CMC) ë° ë§ˆì»¤ ì œì™¸ìœ¨ (MER)ì„ í¬í•¨í•œ ë³´ì™„ì ì¸ ë©”íŠ¸ë¦­ì„ ì‚¬ìš©í•˜ì—¬ í‰ê°€ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ê²°ê³¼ëŠ” ëª…í™•í•œ ì„±ëŠ¥ í”„ë¡œí•„ì„ ë³´ì—¬ì¤ë‹ˆë‹¤: PCAëŠ” ë¹ ë¥¸ ê¸°ì¤€ì„ ì œê³µí•˜ë©°, NMFëŠ” ë§ˆì»¤ í’ë¶€ì„±ì„ ê·¹ëŒ€í™”ì‹œí‚¤ê³ , VAEëŠ” ì¬êµ¬ì„±ê³¼ í•´ì„ê°€ëŠ¥ì„±ì„ ê· í˜•ìˆê²Œ ìœ ì§€í•˜ë©°, ì˜¤í† ì¸ì½”ë”ëŠ” ì¤‘ê°„ ì§€ì ì„ ì°¨ì§€í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” íŒŒë ˆí†  ìµœì  ë¶„ì„ì„ ì‚¬ìš©í•˜ì—¬ ì²´ê³„ì ì¸ í•˜ì´í¼íŒŒë¼ë¯¸í„° ì„ íƒì„ ì œê³µí•˜ê³ , MERì— ë”°ë¥¸ ì¬í• ë‹¹ì´ ëª¨ë“  ë°©ë²•ì—ì„œ ìƒë¬¼í•™ì  ì¶©ì‹¤ì„±ì„ í–¥ìƒì‹œí‚¤ëŠ” ë°©ë²•ì„ ë³´ì—¬ì£¼ë©°, CMC ì ìˆ˜ê°€ í‰ê· ì ìœ¼ë¡œ 12%ê¹Œì§€ í–¥ìƒë˜ëŠ” ê²ƒì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ í”„ë ˆì„ì›Œí¬ëŠ” íŠ¹ì • ê³µê°„ ì „ì‚¬ì²´í•™ ë¶„ì„ì— ë§ê²Œ ì¡°ì •ëœ ì°¨ì› ì¶•ì†Œ ë°©ë²•ì˜ ì›ì¹™ì ì¸ ì„ íƒì„ ê°€ëŠ¥í•˜ê²Œ í•©ë‹ˆë‹¤.

## ğŸ“ ìš”ì•½

ì´ ì—°êµ¬ëŠ” í‘œì¤€ PCA ì ‘ê·¼ë²•ì„ ë„˜ì–´ ê³µê°„ ì „ì‚¬ì²´í•™ì—ì„œ ì°¨ì› ì¶•ì†Œ ê¸°ìˆ ì„ í‰ê°€í•˜ê¸° ìœ„í•œ í†µí•©ëœ í”„ë ˆì„ì›Œí¬ë¥¼ ì†Œê°œí•œë‹¤. ì´ ì—°êµ¬ì—ì„œëŠ” cholangiocarcinoma Xenium ë°ì´í„°ì…‹ì„ ì‚¬ìš©í•˜ì—¬ PCA, NMF, autoencoder, VAE, ë° ë‘ í•˜ì´ë¸Œë¦¬ë“œ ì„ë² ë”© ë°©ë²•ì„ ë¹„êµí•˜ì˜€ë‹¤. ì ì¬ ì°¨ì›($k$=5-40)ê³¼ í´ëŸ¬ìŠ¤í„°ë§ í•´ìƒë„($\rho$=0.1-1.2)ë¥¼ ì²´ê³„ì ìœ¼ë¡œ ë³€í™”ì‹œí‚¤ë©´ì„œ ê° êµ¬ì„±ì€ ì¬êµ¬ì„± ì˜¤ì°¨, ì„¤ëª…ëœ ë¶„ì‚°, í´ëŸ¬ìŠ¤í„° ì‘ì§‘ë ¥, ê·¸ë¦¬ê³  ë‘ ê°€ì§€ ìƒˆë¡œìš´ ìƒë¬¼í•™ì  ì¸¡ì •ì¹˜ì¸ Cluster Marker Coherence (CMC)ì™€ Marker Exclusion Rate (MER)ë¥¼ ì‚¬ìš©í•˜ì—¬ í‰ê°€ë˜ì—ˆë‹¤. ê²°ê³¼ëŠ” PCAê°€ ë¹ ë¥¸ ê¸°ì¤€ì„ ì„ ì œê³µí•˜ê³ , NMFê°€ ë§ˆì»¤ í’ë¶€ì„±ì„ ê·¹ëŒ€í™”í•˜ë©°, VAEê°€ ì¬êµ¬ì„±ê³¼ í•´ì„ê°€ëŠ¥ì„±ì„ ê· í˜•ìˆê²Œ ìœ ì§€í•˜ëŠ” ê²ƒì„ ë³´ì—¬ì£¼ì—ˆë‹¤. autoencoderëŠ” ì¤‘ê°„ ì§€ì ì„ ì°¨ì§€í•œë‹¤. Pareto ìµœì  ë¶„ì„ì„ ì‚¬ìš©í•˜ì—¬ ì²´ê³„ì ì¸ í•˜ì´í¼íŒŒë¼ë¯¸í„° ì„ íƒì„ ì œê³µí•˜ê³ , MERì— ë”°ë¥¸ ì¬í• ë‹¹ì´ ëª¨ë“  ë°©ë²•ì—ì„œ ìƒë¬¼í•™ì  ì¶©ì‹¤ì„±ì„ í–¥ìƒì‹œí‚¤ëŠ” ê²ƒì„ ë³´ì—¬ì£¼ì—ˆë‹¤. ì´ í”„ë ˆì„ì›Œí¬ëŠ” íŠ¹ì • ê³µê°„ ì „ì‚¬ì²´í•™ ë¶„ì„ì— ë§ì¶˜ ì°¨ì› ì¶•ì†Œ ë°©ë²•ì˜ ì›ì¹™ì ì¸ ì„ íƒì„ ê°€ëŠ¥í•˜ê²Œ í•œë‹¤.

## ğŸ¯ ì£¼ìš” í¬ì¸íŠ¸


- 1. ê³µê°„ ì „ì‚¬ì²´í•™ì—ì„œ PCA, NMF, autoencoder, VAE ë° ë‘ í•˜ì´ë¸Œë¦¬ë“œ ì„ë² ë”© ë°©ë²•ì„ ë²¤ì¹˜ë§ˆí‚¹í•˜ì—¬ ê°ê°ì˜ ì„±ëŠ¥ í”„ë¡œí•„ì„ í™•ì¸í•¨.

- 2. ìƒˆë¡œìš´ ìƒë¬¼í•™ì ìœ¼ë¡œ ë™ê¸°ë¶€ì—¬ëœ ì¸¡ì • í•­ëª©ì„ ì‚¬ìš©í•˜ì—¬ ê° êµ¬ì„±ì„ í‰ê°€í•˜ê³  MERì„ í™œìš©í•œ ì¬í• ë‹¹ì´ ìƒë¬¼í•™ì  ì‹ ë¢°ë„ í–¥ìƒì— ë„ì›€ì´ ë¨.

- 3. Pareto ìµœì  ë¶„ì„ì„ í†µí•´ ì²´ê³„ì ì¸ í•˜ì´í¼íŒŒë¼ë¯¸í„° ì„ íƒì„ ì œê³µí•˜ê³ , CMC ì ìˆ˜ê°€ í‰ê·  12% í–¥ìƒë˜ëŠ” ê²ƒì„ ë³´ì—¬ì¤Œ.


---

*Generated on 2025-09-18 16:41:15*